Drug cocktail aims to shrink stomach tumors before surgery in small trial
NCT ID NCT07151209
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and chemotherapy (SOX) in 20 people with a specific type of advanced stomach or gastroesophageal junction cancer (MSI-H/dMMR). The goal is to see if this treatment can completely eliminate the tumor before surgery, potentially improving outcomes. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab, tuvonralimab, lenvatinib, and SOX chemotherapy (oxaliplatin and S-1)
What this could lead to
If successful, this combination could shrink advanced gastric tumors enough to allow surgical removal, potentially improving long-term survival.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The drug combination also carries risks of serious side effects like immune reactions and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••